DALLAS, September 8, 2014 /PRNewswire/ --
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - United Arab Emirates is a 266 pages, 2014 market research report now available with ReportsnReports.com at http://www.reportsnreports.com/reports/297438-countryfocus-healthcare-regulatory-and-reimbursement-landscape-united-arab-emirates.html . This research says the United Arab Emirates (UAE) is second only to Saudi Arabia in terms of pharmaceutical investment in Middle East countries, with the creation of tax-exempt drug development zones helping to ensure excellent growth prospects. It states that medical tourism, straightforward regulatory guidelines and increasing healthcare expenditure will also be key factors driving the UAE's pharmaceutical market, which is forecast to be worth $3.7 billion by 2020.
In 2013, the UAE's population stood at 9 million, an increase from 8.1 million in 2008. The United Arab Emirates' pharmaceutical market was estimated to have been worth $2.4 billion in 2013 and is expected to reach $3.7 billion by 2020 at a projected Compound Annual Growth Rate (CAGR) of 5.3%. The UAE's medical device market was valued at approximately $600.2m in 2008, and $733.3m in 2013. The medical device market is estimated to reach $978.9m in 2020 at a CAGR of 4.2% from 2014. The positive trends in UAE's healthcare market can primarily be attributed to the increasing coverage of healthcare insurance and government initiatives to improve healthcare facilities.
As per the director of healthcare industry dynamics of the team that worked on CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - United Arab Emirates research report, UAE is benefiting from the establishment of health-related free zones, such as the Dubai Biotechnology and Research Park (DuBiotech), which have encouraged global pharmaceutical players to set up regional centers in the country. The director explains "The big draw for companies located in DuBiotech is that they receive a 100% exemption on corporate and personal tax, which is guaranteed for 50 years. Expenditure on pharmaceutical research and development in the UAE is very low compared to other countries, meaning that novel medicines must be imported at a high price, but projects such as DuBiotech may help to redress the balance."
The key companies covered in CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - United Arab Emirates research report for the pharmaceutical market are Julphar, Neopharma, Pfizer, GlaxoSmithKline and Novartis. The key players covered for the medical devices market are Medtronic, Siemens Healthcare, F. Hoffmann-La Roche, Abbott Laboratories and Boston Scientific Corporation. Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=297438 .
The UAE's healthcare market will also be boosted by medical tourists, of which Dubai is aiming to have more than 20 million by 2020, according to UAEinteract. The director in charge further says: "Affluent patients from across the globe are willing to travel to find the best hospitals and healthcare facilities. The UAE offers a world-class service in terms of availability and quality, and is easily accessible to the rest of the world thanks to its airline and airport infrastructure. The Dubai Health Care City is providing a platform for increased medical tourism and will bring more revenue to Dubai and the UAE, driving market growth at a much faster rate than historically."
Scope of CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - United Arab Emirates 2014 research report includes:
- Overview of the pharmaceutical and medical device markets, including size, segmentation and key drivers and barriers
- Profile and SWOT analysis of the major players in the pharmaceutical and medical devices market. The key players covered for the pharmaceutical market are Julphar, Neopharma, Pfizer, GlaxoSmithKline and Novartis. The key players covered for the medical devices market are Medtronic, Siemens Healthcare, F. Hoffmann-La Roche, Abbott Laboratories and Boston Scientific Corporation.
- An insightful review of the reimbursement and regulatory landscape, covering the healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices
- Detailed analysis of the political and economic environment, including economic indicators, demographics, healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the healthcare market
Similar other healthcare market reports focused on a particular country and its regulatory and reimbursement landscape available with ReportsnReports.com include:
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Saudi Arabia is a 246 pages research report published in July 2014 and says that the value of the pharmaceutical market in Saudi Arabia was $4 billion in 2013, and it is expected to increase at a CAGR of 5.8% to reach approximately $5.9 billion in 2020. The major market share is garnered by imports of over-the-counter drugs and patented products. Profiles and SWOT analyses of major players in the pharmaceutical market (GlaxoSmithKline, Pfizer, Novartis, SPIMACO and Tabuk) as well as medical device market (Siemens Healthcare, GE Healthcare, F. Hoffmann-La Roche, Philips Healthcare and Abbott Laboratories) of Saudi Arabia are covered in the report available at http://www.reportsnreports.com/reports/291513-countryfocus-healthcare-regulatory-and-reimbursement-landscape-saudi-arabia.html .
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Mexico is another report of 279 pages that says value of the Mexican pharmaceutical market amounted to $14 billion, in 2013, and is expected to increase at a CAGR of 7% to reach approximately $22.5 billion in 2020. The medical device market was worth $3.6 billion in 2013 and is projected to reach $5.4 billion in 2020, at a CAGR of 6.1%. The key players covered for the pharmaceutical market in Mexico are Pfizer, Sanofi, Merck, Novartis and Genomma Lab Internacional. The key players covered for the Mexican medical devices market are Fresenius Medical Care, F. Hoffmann-La Roche, DePuy Companies, Siemens Healthcare and Medtronic. Complete report is available at http://www.reportsnreports.com/reports/291512-countryfocus-healthcare-regulatory-and-reimbursement-landscape-mexico.html .
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Australia is a September 2014 report of 263 pages that forecasts the pharmaceutical market in Australia to reach $32 billion by 2020. Australian medical devices industry is projected to grow at a CAGR of 4.9% to $10.4 billion by 2020. This report covers profiles and SWOT analyses of the major players in the pharmaceutical market: Pfizer, AstraZeneca, Novartis, Sanofi and Alphapharm; and medical device market: Siemens Healthcare, GE Healthcare, Medtronic, DePuy companies and F.Hoffmann-La Roche.
ReportsnReports.com is an online market research reports library of 450,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.
Connect With Us on:
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252